Duchenne muscular dystrophy complicated by acute septic appendicitis in children: one case report

References:

[1] Mercuri E,B?nnemann CG,Muntoni F.Muscular dystrophies[J].Lancet,2019,394(10213):2025-2038.DOI:10.1016/S0140-6736(19)32910-1.
[2] Birnkrant DJ,Bushby K,Bann CM,et al.Diagnosis and management of Duchenne muscular dystrophy,part 2:respiratory,cardiac,bone health,and orthopaedic management[J].Lancet Neurol,2018,17(4):347-361.DOI:10.1016/S1474-4422(18)30025-5.
[3] Salmaninejad A,Jafari Abarghan Y,Bozorg Qomi S,et al.Common therapeutic advances for Duchenne muscular dystrophy (DMD)[J].Int J Neurosci,2021,131(4):370-389.DOI:10.1080/00207454.2020.1740218.
[4] Aartsma-Rus A,Van Deutekom JCT,Fokkema IF,et al.Entries in the Leiden Duchenne muscular dystrophy mutation database:an overview of mutation types and paradoxical cases that confirm the reading-frame rule[J].Muscle Nerve,2006,34(2):135-144.DOI:10.1002/mus.20586.
[5] Markati T,Oskoui M,Farrar MA,et al.Emerging therapies for Duchenne muscular dystrophy[J].Lancet Neurol,2022,21(9):814-829.DOI:10.1016/S1474-4422(22)00125-9.
[6] 周璟娜，黄国英.杜氏肌营养不良患者心脏损害的研究进展[J].国际儿科学杂志，2016,43(2):105-108.DOI:10.3760/cma.j.issn.1673-4408.2016.02.005. Zhou JN，Huang GY.Research advances of cardiac injury in patients with Duchenne muscular dystrophy[J].Int J Pediatr,2016,43(2):105-108.DOI:10.3760/cma.j.issn.1673-4408.2016.02.005.
[7] Turner PR,Westwood T,Regen CM,et al.Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice[J].Nature,1988,335(6192):735-738.DOI:10.1038/335735a0.
[8] 赵建生，王准胜.氯胺酮可疑诱发小儿恶性高热一例[J].中华麻醉学杂志，2001,21(2):76.DOI:10.3760/j.issn:0254-1416.2001.02.022. Zhao JS,Wang ZS.Malignant hyperthermia in a child suspected to be induced by ketamine:one case report[J].Chin J Anesthesiol,2001,21(2):76.DOI:10.3760/j.issn:0254-1416.2001.02.022.
[9] Chamley D,Pollock NA,Stowell KM,et al.Malignant hyperthermia in infancy and identification of novel RYR1 mutation[J].Br J Anaesth,2000,84(4):500-504.DOI:10.1093/oxfordjournals.bja.a013478.
[10] Urwyler A.Malignant hyperthermia:presymptomatic screening and treatment 2011[J].Eur J Anaesthesiol,2011,28(4):237-239.DOI:10.1097/EJA.0b013e3283433b9f.
[11] Birnkrant DJ.The American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation[J].Pediatrics,2009,123(S4):S242-S244.DOI:10.1542/peds.2008-2952J.
[12] Kamdar F,Garry DJ.Dystrophin-deficient cardiomyopathy[J].J Am Coll Cardiol,2016,67(21):2533-2546.DOI:10.1016/j.jacc.2016.02.081.
[13] McDonald CM,Henricson EK,Abresch RT,et al.Long-term effe-cts of glucocorticoids on function,quality of life,and survival in patients with Duchenne muscular dystrophy:a prospective cohort study[J].Lancet,2018,391(10119):451-461.DOI:10.1016/S0140-6736(17)32160-8.
[14] Birnkrant DJ,Bushby K,Bann C,et al.Anesthetic management of patients with Duchenne muscular dystrophy[J].Int Anesthesiol Clin,2020,58(3):45-58.